SPIMACO turns to net profit of SAR 109.5 mln in 2020

23/03/2021 Argaam Exclusive

View other reports

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) reported a net profit after Zakat and tax of SAR 109.5 million for 2020 against a net loss of SAR 484 million last year.

Financials (M)

Item	2019	2020	Change‬
Revenues	1,486.85	1,555.29	4.6 %
Gross Income	497.64	690.48	38.8 %
Operating Income	(80.10)	143.22	278.8 %
Net Income	(439.74)	124.79	128.4 %
Average Shares	120.00	120.00	-
EPS (Riyals)	(3.66)	1.04	128.4 %

The profit growth was driven by a 5% year-on-year (YoY) rise in sales revenue, amid better private sector sales, which was further supported by a 12% YoY decline in the cost of sales. Selling and marketing expenses decreased by SAR 34 million, or 10% YoY, with the impairment of trade receivables declining by SAR 94 million, or 98% YoY.

The company also reported lower finance costs and an increase of SAR 52 million in its profit share from associates and joint venture companies.

Moreover, some of the non-recurring expenses recorded in 2019 had a positive impact on 2020 performance, as these expenses included impairment of goodwill of SAR 137 million and financial guarantee expenses of SAR 108 million.

In Q4 2020, SPIMACO narrowed net losses by 90.6% to SAR 28.4 million, from SAR 303.95 million in prior-year period.

Shareholders’ equity, excluding minority interest, decreased by 1.4% YoY to SAR 1.915 billion in 2020.

Current Quarter Comparison (M)

Compared With The

Item	Q4 2019	Q4 2020	Change‬
Revenues	344.32	378.52	9.9 %
Gross Income	79.28	145.55	83.6 %
Operating Income	(78.77)	2.91	103.7 %
Net Income	(259.65)	(13.20)	94.9 %
Average Shares	120.00	120.00	-
EPS (Riyals)	(2.16)	(0.11)	94.9 %

Item	Q3 2020	Q4 2020	Change‬
Revenues	372.91	378.52	1.5 %
Gross Income	195.71	145.55	(25.6 %)
Operating Income	70.05	2.91	(95.8 %)
Net Income	67.41	(13.20)	(119.6 %)
Average Shares	120.00	120.00	-
EPS (Riyals)	0.56	(0.11)	(119.6 %)

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Net Income	Change	EPS(Riyal)
Q1 2011	252.08	(8.1 %)	123.51	3.9 %	45.71	0.9 %	0.38
Q2 2011	292.08	15.7 %	123.61	23.0 %	60.75	41.0 %	0.51
Q3 2011	209.24	9.3 %	106.76	24.3 %	29.75	64.6 %	0.25
Q4 2011	375.82	17.6 %	206.69	14.1 %	74.06	5.7 %	0.62
2011	1,129.22	8.8 %	560.57	15.2 %	211.44	19.8 %	1.76
Q1 2012	303.14	20.3 %	153.21	24.0 %	56.45	23.5 %	0.47
Q2 2012	286.64	(1.9 %)	140.91	14.0 %	90.14	48.4 %	0.75
Q3 2012	227.40	8.7 %	113.28	6.1 %	32.33	8.7 %	0.27
Q4 2012	365.97	(2.6 %)	211.16	2.2 %	53.73	(27.5 %)	0.45
2012	1,183.15	4.8 %	618.56	10.3 %	232.65	10.0 %	1.94
Q1 2013	361.37	19.2 %	184.62	20.5 %	63.15	11.9 %	0.53
Q2 2013	344.22	20.1 %	179.12	27.1 %	113.71	26.1 %	0.95
Q3 2013	222.91	(2.0 %)	118.64	4.7 %	34.19	5.8 %	0.28
Q4 2013	382.01	4.4 %	226.14	7.1 %	57.01	6.1 %	0.48
2013	1,310.50	10.8 %	708.52	14.5 %	266.82	14.7 %	2.22
Q1 2014	405.21	12.1 %	206.72	12.0 %	91.17	44.4 %	0.76
Q2 2014	371.14	7.8 %	193.14	7.8 %	97.72	(14.1 %)	0.81
Q3 2014	266.02	19.3 %	134.45	13.3 %	36.69	7.3 %	0.31
Q4 2014	431.06	12.8 %	261.80	15.8 %	91.29	60.1 %	0.76
2014	1,470.19	12.2 %	794.54	12.1 %	316.85	18.8 %	2.64
Q1 2015	432.20	6.7 %	225.86	9.3 %	99.39	9.0 %	0.83
Q2 2015	435.80	17.4 %	210.95	9.2 %	237.63	143.2 %	1.98
Q3 2015	308.27	15.9 %	131.32	(2.3 %)	29.16	(20.5 %)	0.24
Q4 2015	520.38	20.7 %	266.38	1.7 %	(9.12)	(110.0 %)	(0.08)
2015	1,705.05	16.0 %	848.60	6.8 %	357.05	12.7 %	2.98
Q1 2016	322.20	(25.4 %)	194.26	(14.0 %)	88.91	(10.5 %)	0.74
Q2 2016	339.54	(22.1 %)	183.58	(13.0 %)	39.61	(83.3 %)	0.33
Q3 2016	257.21	(16.6 %)	140.54	7.0 %	4.76	(83.7 %)	0.04
Q4 2016	339.59	(34.7 %)	194.16	(27.1 %)	143.48	1673.8 %	1.20
2016	1,258.55	(26.2 %)	712.54	(16.0 %)	276.76	(22.5 %)	2.31
Q1 2017	393.10	22.0 %	212.58	9.4 %	101.22	13.8 %	0.84
Q2 2017	304.63	(10.3 %)	156.13	(15.0 %)	46.56	17.5 %	0.39
Q3 2017	277.62	7.9 %	128.68	(8.4 %)	(17.03)	(457.9 %)	(0.14)
Q4 2017	410.69	20.9 %	207.07	6.7 %	66.61	(53.6 %)	0.56
2017	1,386.04	10.1 %	704.46	(1.1 %)	197.37	(28.7 %)	1.64
Q1 2018	390.79	(0.6 %)	197.32	(7.2 %)	55.23	(45.4 %)	0.46
Q2 2018	295.62	(3.0 %)	155.28	(0.5 %)	22.67	(51.3 %)	0.19
Q3 2018	224.95	(19.0 %)	137.89	7.2 %	(12.12)	28.8 %	(0.10)
Q4 2018	600.79	46.3 %	127.79	(38.3 %)	19.01	(71.5 %)	0.16
2018	1,503.32	8.5 %	608.52	(13.6 %)	76.58	(61.2 %)	0.64
Q1 2019	444.80	13.8 %	152.43	(22.7 %)	(21.71)	(139.3 %)	(0.18)
Q2 2019	355.03	20.1 %	95.10	(38.8 %)	(186.49)	(922.8 %)	(1.55)
Q3 2019	342.69	52.3 %	170.82	23.9 %	28.11	332.0 %	0.23
Q4 2019	344.32	(42.7 %)	79.28	(38.0 %)	(259.65)	(1466.1 %)	(2.16)
2019	1,486.85	(1.1 %)	497.64	(18.2 %)	(439.74)	(674.2 %)	(3.66)
Q1 2020	475.72	7.0 %	198.73	30.4 %	45.60	310.1 %	0.38
Q2 2020	328.14	(7.6 %)	150.49	58.2 %	24.98	113.4 %	0.21
Q3 2020	372.91	8.8 %	195.71	14.6 %	67.41	139.8 %	0.56
Q4 2020	378.52	9.9 %	145.55	83.6 %	(13.20)	94.9 %	(0.11)
2020	1,555.29	4.6 %	690.48	38.8 %	124.79	128.4 %	1.04

Period	Revenues	Change	Gross Income	Change	Net Income	Change	EPS(Riyal)
2011	1,129.22	8.8 %	560.57	15.2 %	211.44	19.8 %	1.76
2012	1,183.15	4.8 %	618.56	10.3 %	232.65	10.0 %	1.94
2013	1,310.50	10.8 %	708.52	14.5 %	266.82	14.7 %	2.22
2014	1,470.19	12.2 %	794.54	12.1 %	316.85	18.8 %	2.64
2015	1,705.05	16.0 %	848.60	6.8 %	357.05	12.7 %	2.98
2016	1,258.55	(26.2 %)	712.54	(16.0 %)	276.76	(22.5 %)	2.31
2017	1,386.04	10.1 %	704.46	(1.1 %)	197.37	(28.7 %)	1.64
2018	1,503.32	8.5 %	608.52	(13.6 %)	76.58	(61.2 %)	0.64
2019	1,486.85	(1.1 %)	497.64	(18.2 %)	(439.74)	(674.2 %)	(3.66)
2020	1,555.29	4.6 %	690.48	38.8 %	124.79	128.4 %	1.04

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2011	48.36 %	18.99 %	17.42 %
Q2 2011	48.73 %	19.12 %	18.44 %
Q3 2011	49.86 %	19.99 %	19.22 %
Q4 2011	49.64 %	19.57 %	18.62 %
2011	49.64 %	19.65 %	18.72 %
Q1 2012	50.01 %	19.86 %	18.73 %
Q2 2012	51.72 %	20.36 %	21.31 %
Q3 2012	51.47 %	20.54 %	21.21 %
Q4 2012	52.28 %	19.56 %	19.66 %
2012	52.28 %	19.56 %	19.66 %
Q1 2013	52.36 %	19.26 %	19.28 %
Q2 2013	52.98 %	18.87 %	20.24 %
Q3 2013	53.58 %	18.66 %	20.45 %
Q4 2013	54.06 %	18.26 %	20.45 %
2013	54.06 %	18.16 %	20.36 %
Q1 2014	53.95 %	17.92 %	21.86 %
Q2 2014	53.91 %	17.74 %	20.28 %
Q3 2014	53.39 %	16.79 %	19.84 %
Q4 2014	54.03 %	18.15 %	21.50 %
2014	54.04 %	18.15 %	21.55 %
Q1 2015	54.34 %	18.90 %	21.67 %
Q2 2015	53.23 %	18.31 %	20.04 %
Q3 2015	51.63 %	17.40 %	19.05 %
Q4 2015	49.19 %	17.17 %	19.11 %
2015	49.77 %	16.85 %	19.02 %
Q1 2016	50.60 %	15.90 %	18.80 %
Q2 2016	52.04 %	15.52 %	16.88 %
Q3 2016	54.52 %	15.09 %	15.79 %
Q4 2016	56.62 %	10.25 %	5.68 %
2016	56.62 %	10.25 %	5.68 %
Q1 2017	54.97 %	9.67 %	3.99 %
Q2 2017	54.34 %	11.85 %	4.64 %
Q3 2017	52.59 %	11.94 %	2.91 %
Q4 2017	50.83 %	14.96 %	9.94 %
2017	50.83 %	14.96 %	9.94 %
Q1 2018	49.81 %	16.45 %	9.97 %
Q2 2018	50.07 %	14.49 %	8.30 %
Q3 2018	52.76 %	15.07 %	9.00 %
Q4 2018	40.89 %	5.68 %	5.61 %
2018	40.48 %	4.92 %	5.09 %
Q1 2019	36.61 %	2.64 %	0.50 %
Q2 2019	31.57 %	(2.89 %)	(5.68 %)
Q3 2019	31.33 %	0.66 %	(2.99 %)
Q4 2019	33.47 %	1.46 %	(13.51 %)
2019	33.47 %	1.46 %	(13.51 %)
Q1 2020	35.84 %	4.49 %	(8.80 %)
Q2 2020	40.20 %	10.74 %	(2.08 %)
Q3 2020	41.04 %	11.13 %	0.55 %
Q4 2020	44.40 %	14.83 %	8.02 %
2020	44.40 %	14.83 %	8.02 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2011	49.64 %	19.65 %	18.72 %
2012	52.28 %	19.56 %	19.66 %
2013	54.06 %	18.16 %	20.36 %
2014	54.04 %	18.15 %	21.55 %
2015	49.77 %	16.85 %	19.02 %
2016	56.62 %	10.25 %	5.68 %
2017	50.83 %	14.96 %	9.94 %
2018	40.48 %	4.92 %	5.09 %
2019	33.47 %	1.46 %	(13.51 %)
2020	44.40 %	14.83 %	8.02 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2011	49.00 %	22.74 %	18.13 %
Q2 2011	42.32 %	13.00 %	20.80 %
Q3 2011	51.02 %	19.57 %	14.22 %
Q4 2011	55.00 %	22.56 %	19.71 %
Q1 2012	50.54 %	23.32 %	18.62 %
Q2 2012	49.16 %	14.95 %	31.45 %
Q3 2012	49.82 %	20.53 %	14.22 %
Q4 2012	57.70 %	19.47 %	14.68 %
Q1 2013	51.09 %	21.68 %	17.48 %
Q2 2013	52.04 %	14.20 %	33.03 %
Q3 2013	53.22 %	19.34 %	15.34 %
Q4 2013	59.20 %	18.05 %	14.92 %
Q1 2014	51.02 %	20.19 %	22.50 %
Q2 2014	52.04 %	13.80 %	26.33 %
Q3 2014	50.54 %	13.97 %	13.79 %
Q4 2014	60.73 %	22.54 %	21.18 %
Q1 2015	52.26 %	22.70 %	23.00 %
Q2 2015	48.40 %	12.42 %	19.81 %
Q3 2015	42.60 %	9.85 %	9.46 %
Q4 2015	51.19 %	20.88 %	21.02 %
Q1 2016	60.29 %	18.36 %	22.80 %
Q2 2016	54.07 %	9.77 %	11.67 %
Q3 2016	54.64 %	6.30 %	1.85 %
Q4 2016	57.18 %	6.04 %	(13.65 %)
Q1 2017	54.08 %	14.94 %	14.01 %
Q2 2017	51.25 %	19.02 %	15.29 %
Q3 2017	46.35 %	7.17 %	(6.13 %)
Q4 2017	50.42 %	17.25 %	12.96 %
Q1 2018	50.49 %	20.19 %	14.13 %
Q2 2018	52.53 %	9.98 %	7.67 %
Q3 2018	61.30 %	8.88 %	(5.39 %)
Q4 2018	21.27 %	(7.08 %)	3.16 %
Q1 2019	34.27 %	7.75 %	(4.88 %)
Q2 2019	26.79 %	(16.60 %)	(21.86 %)
Q3 2019	49.85 %	22.90 %	8.20 %
Q4 2019	23.03 %	(9.36 %)	(37.65 %)
Q1 2020	41.77 %	16.99 %	9.59 %
Q2 2020	45.86 %	10.09 %	7.61 %
Q3 2020	52.48 %	23.49 %	18.08 %
Q4 2020	38.45 %	7.68 %	(3.49 %)

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2011	120.00	1.47	1.47	25.41
Q2 2011	120.00	1.62	1.62	27.29
Q3 2011	120.00	1.72	1.72	25.92
Q4 2011	120.00	1.75	1.75	26.50
Q1 2012	120.00	1.84	1.84	30.26
Q2 2012	120.00	2.09	2.09	25.75
Q3 2012	120.00	2.11	2.11	26.24
Q4 2012	120.00	1.94	1.94	25.28
Q1 2013	120.00	1.99	1.99	27.18
Q2 2013	120.00	2.19	2.19	26.14
Q3 2013	120.00	2.21	2.21	27.35
Q4 2013	120.00	2.23	2.23	32.18
Q1 2014	120.00	2.47	2.47	32.96
Q2 2014	120.00	2.33	2.33	33.21
Q3 2014	120.00	2.35	2.35	35.74
Q4 2014	120.00	2.64	2.64	28.75
Q1 2015	120.00	2.71	2.71	27.84
Q2 2015	120.00	3.87	2.61	28.72
Q3 2015	120.00	3.81	2.55	24.87
Q4 2015	120.00	2.98	2.70	22.17
Q1 2016	120.00	2.89	2.49	20.84
Q2 2016	120.00	1.24	2.10	20.49
Q3 2016	120.00	1.03	1.89	20.40
Q4 2016	120.00	2.31	0.60	22.59
Q1 2017	120.00	2.41	0.44	23.27
Q2 2017	120.00	2.47	0.50	21.52
Q3 2017	120.00	2.29	0.32	22.01
Q4 2017	120.00	1.64	1.15	22.78
Q1 2018	120.00	1.26	1.15	25.04
Q2 2018	120.00	1.06	0.95	25.74
Q3 2018	120.00	1.10	0.99	24.32
Q4 2018	120.00	0.71	0.71	21.17
Q1 2019	120.00	0.07	0.07	22.80
Q2 2019	120.00	(1.68)	(0.77)	19.63
Q3 2019	120.00	(1.34)	(0.43)	18.36
Q4 2019	120.00	(3.66)	(1.67)	16.20
Q1 2020	120.00	(3.10)	(1.11)	14.14
Q2 2020	120.00	(1.34)	(0.26)	14.67
Q3 2020	120.00	(1.01)	0.07	15.63
Q4 2020	120.00	1.04	1.04	15.96

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2011	120.00	1.76	1.76	26.50
2012	120.00	1.94	1.94	25.28
2013	120.00	2.22	2.22	32.18
2014	120.00	2.64	2.64	28.75
2015	120.00	2.98	2.70	22.17
2016	120.00	2.31	0.60	22.59
2017	120.00	1.64	1.15	22.78
2018	120.00	0.64	0.64	21.17
2019	120.00	(3.66)	(1.67)	16.20
2020	120.00	1.04	1.04	15.96

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2011	17.65	17.65	1.02
Q2 2011	15.68	15.68	0.93
Q3 2011	14.41	14.41	0.96
Q4 2011	15.03	15.03	0.99
Q1 2012	17.92	17.92	1.09
Q2 2012	12.56	12.56	1.02
Q3 2012	13.70	13.70	1.10
Q4 2012	14.74	14.74	1.13
Q1 2013	13.60	13.60	1.00
Q2 2013	15.51	15.51	1.30
Q3 2013	15.70	15.70	1.27
Q4 2013	19.02	19.02	1.32
Q1 2014	19.07	19.07	1.43
Q2 2014	19.29	19.29	1.36
Q3 2014	21.41	21.41	1.41
Q4 2014	12.89	12.89	1.18
Q1 2015	14.78	14.78	1.44
Q2 2015	11.59	17.18	1.56
Q3 2015	9.46	14.14	1.45
Q4 2015	11.16	12.29	1.50
Q1 2016	11.15	12.96	1.55
Q2 2016	29.96	17.69	1.81
Q3 2016	30.18	16.49	1.53
Q4 2016	17.72	68.63	1.81
Q1 2017	15.03	81.82	1.56
Q2 2017	14.32	70.59	1.64
Q3 2017	14.43	More than 100	1.50
Q4 2017	18.25	26.14	1.32
Q1 2018	24.34	26.70	1.23
Q2 2018	30.03	33.56	1.24
Q3 2018	28.37	31.57	1.29
Q4 2018	41.61	41.61	1.39
Q1 2019	More than 100	More than 100	1.21
Q2 2019	NEG	NEG	1.35
Q3 2019	NEG	NEG	1.43
Q4 2019	NEG	NEG	1.68
Q1 2020	NEG	NEG	1.91
Q2 2020	NEG	NEG	1.98
Q3 2020	NEG	More than 100	2.34
Q4 2020	37.70	37.70	2.46

Period	P/E	Adjusted P/E	Price/book
2011	14.95	14.95	0.99
2012	14.74	14.74	1.13
2013	19.11	19.11	1.32
2014	12.89	12.89	1.18
2015	11.16	12.29	1.50
2016	17.72	68.63	1.81
2017	18.25	26.14	1.32
2018	46.07	46.07	1.39
2019	NEG	NEG	1.68
2020	37.70	37.70	2.46

Business Segments (Million)

Compared With The

Period	Pharmaceutical Manufacturing	healthy services and other	Trading & Distribution Services	Contract manufacturing arrangements	Medical & Pharmaceutical production segment	Investment activity	Eliminations
Q1 2011	-	-	-	-	252.08	-	-
Q2 2011	-	-	-	-	292.08	-	-
Q3 2011	-	-	-	-	209.24	-	-
Q4 2011	-	-	-	-	375.82	-	-
Q1 2012	-	-	-	-	303.14	-	-
Q2 2012	-	-	-	-	286.65	-	-
Q3 2012	-	-	-	-	227.40	-	-
Q4 2012	-	-	-	-	365.97	-	-
Q1 2013	-	-	-	-	361.37	-	-
Q2 2013	-	-	-	-	344.22	-	-
Q3 2013	-	-	-	-	222.91	-	-
Q4 2013	-	-	-	-	382.01	-	-
Q1 2014	-	-	-	-	405.21	-	-
Q2 2014	-	-	-	-	374.14	-	-
Q3 2014	-	-	-	-	266.02	-	-
Q4 2014	-	-	-	-	427.82	-	-
Q1 2015	-	-	-	-	432.29	14.84	-
Q2 2015	-	-	-	-	436.99	195.93	-
Q3 2015	-	-	-	-	308.38	9.55	-
Q4 2015	-	-	-	-	529.24	-	-
Q1 2016	-	-	-	-	513.97	25.27	-
Q2 2016	-	-	-	-	494.92	9.41	-
Q3 2016	-	-	-	-	100.39	6.23	-
Q4 2016	-	-	-	-	401.35	247.84	-
Q1 2017	-	-	-	-	446.00	50.90	(51.45)
Q2 2017	-	-	-	-	350.01	1.39	(43.30)
Q3 2017	-	-	-	-	317.29	4.01	(36.78)
Q4 2017	-	-	-	-	486.15	-	(54.74)
Q1 2018	-	-	-	-	450.19	7.00	(57.49)
Q3 2018	172.41	34.26	1.75	16.54	-	-	-
Q1 2019	419.76	22.19	2.03	0.82	-	-	-
Q2 2019	334.00	19.00	0.91	1.12	-	-	-
Q3 2019	313.52	20.79	7.10	1.29	-	-	-
Q1 2020	449.65	22.39	1.55	2.13	-	-	-
Q2 2020	295.05	27.32	5.12	0.65	-	-	-
Q3 2020	348.38	22.04	0.75	1.74	-	-	-
Q4 2020	349.04	20.89	6.83	1.76	-	-	-

Period	Pharmaceutical Manufacturing	healthy services and other	Trading & Distribution Services	Contract manufacturing arrangements	Medical & Pharmaceutical production segment	Investment activity	Eliminations
2011	-	-	-	-	1,129.22	-	-
2012	-	-	-	-	1,183.15	-	-
2013	-	-	-	-	1,310.50	-	-
2014	-	-	-	-	1,470.19	-	-
2015	-	-	-	-	1,706.80	115.14	-
2016	-	-	-	-	1,510.63	288.74	(244.41)
2017	-	-	-	-	1,599.45	61.92	(186.28)
2018	1,414.72	78.37	5.02	5.22	-	-	-
2019	1,397.28	77.87	5.93	5.76	-	-	-
2020	1,442.13	92.64	14.25	6.27	-	-	-

Financial Ratios

	Current
Market Cap (M Riyal)	3,510.00
Enterprise Value (EV) (M)	4,591.48
Shares Outstanding ((M))	120.00
EPS ( Riyal) (TTM)	(0.27)
Book Value (BV) ( Riyal)	12.89
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	Neg
P/E (TTM)	NEG
Price/book	2.27
Return on Average Assets (%) (TTM)	(0.76 )
Return on Average Equity (%) (TTM)	(2.09 )

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

SPIMACO turns to net profit of SAR 109.5 mln in 2020

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2020 Q4

Financial Ratios

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

SPIMACO turns to net profit of SAR 109.5 mln in 2020

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q4 2020

Revenue by Business Segment (Latest) 2020 Q4

Financial Ratios

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)